Kazakov YM, Potiazhenko MM, Nastroga TV. TREATMENT OPTIMIZATION IN MANAGEMENT OF COMBINED PATHOLOGY - ARTERIAL HYPERTENSION AND
POST-COVID SYNDROME IN ELDERLY PATIENTS.
Wiad Lek 2023;
76:1543-1548. [PMID:
37622495 DOI:
10.36740/wlek202307105]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/26/2023]
Abstract
OBJECTIVE
The aim: Purpose of the study. Our research is aimed at the increase in the treatment effectiveness for combined pathology, namely, arterial hypertension (AH) and post-COVID syndrome in elderly patients at the stage of providing medical care by family medicine general practitioners with the use of statins, anti¬platelet agents, as well as endothelial-protective drug - L-arginine and anxiolytic effect - mebicar against the background of basic antihypertensive therapy.
PATIENTS AND METHODS
Materials and methods: The study included treatment and observation of 50 elderly patients with hypertension and post-COVID syndrome. The average age was 68.7«1.89 years.
RESULTS
Results: The use of mebicar with moderate tranquilizing (anxiolytic) effect and endothelium-protector - L-arginine in the comprehensive treatment of elderly patients with combined pathology - AH and post-COVID syndrome contributed to the elimination of the main clinical symptoms (headache, poor sleep) in a shorter time; provided significant decrease in the level of systolic blood pressure, reactive anxiety, the decrease in total blood cholesterol, and improvement in blood rheology.
CONCLUSION
Conclusions: Treatment optimization for combined pathology - arterial hypertension and post-COVID syndrome in elderly patients with the use of L-arginine and mebicar in comprehensive treatment, improves the quality of patients' life, reduces the treatment duration.
Collapse